Scrip's 2000 Yearbook is an invaluable addition to your personal, company or business library. It is a one-stop source of facts, data and statistics on pharmaceutical markets, products and companies worldwide. This easy-to-use, two-volume guide will enable you to: have an instant and informed view of the pharmaceutical industry; understand market trends and estimate market sizes; analyse new products and review recent developments and assess competitors and their products.
Scrip's 2000 Yearbook is divided into five key
sections:
1. Major issues affecting the pharmaceutical industry in 1999,
including data on the values of leading markets, new chemical
entities and new product development
2. Cross-industry statistics drawing together data on the size and estimated growth of world markets, the top ranked products and companies, R&D expenditure and launch times
3. Actual revenues and sales forecasts for therapeutic markets worldwide and information on patient populations
4. Financial and other information about 30 of the leading companies worldwide as listed by Scrip's 1999 Pharmaceutical Company League Tables
5.Valuable industry and market data on individual countries and regions
New for 2000: keyword index for your ease of use!
PUBLICATION: FEBRUARY 2000
REFERENCE:BS1044E
PAGES: 600+
PRICE: �395/$830/�95,000
CONTENTS - Volume 1
Part I: REVIEW OF 1999
1.1: Opinion: Will There Be Jam Tomorrow? 1.2: The Year in Review: Pharma Industry Comes Under Increasing Strain 1.3: Europe: Single Pharma Market Remains a Dream? 1.4: EU Legislation: Trials and Tribulations 1.5: Generics: Persistence Pays Off 1.6: Eastern Europe: Building Trust in EU Expansion Talks 1.7: Eastern Europe: Generics Firms Face Fierce Competition 1.8: US Congress: Drug Prices Under Mounting Pressure 1.9: US FDA: Henney Ushers in a Modernised FDA 1.10: Canada: Provincial Government Gets Tough on Pricing 1.11: Japan: Lobbying Limits State Curbs on Health Spend 1.12: South-East Asia: Brighter Outlook but Cost Controls Loom 1.13: World Market Data: Healthy Growth for World Pharma Sales 1.14: Developing World: Access to Medicines Rises Up International Agenda 1.15: World Health: Fresh Hope in Search for Health for All 1.16: World Markets: Patents, Politics and the Provision of Drugs 1.17: Top Companies: Merck Holds Top Position - For the Last Time? 1.18: Merger Activity: Managing the Innovation Gap with M&As 1.19: Is the Rough Ride Over for Biotech? 1.20: UK Biotech: Battling it Out in European Biotech 1.21: E-Commerce: Pharma Lags Behind in the E-Environment 1.22: Lifestyle Drugs: A Year in the Life. . . 1.23: Diabetes: Is it All Glitter for the Glitazones? 1.24: Cancer Patients Start to See the Benefits of Biology 1.25: A Revolution in Rheumatology 1.26: Successes in 1999: Preventive Products Reap Most Rewards 1.27: Setbacks in 1999: Withdrawals Without Widespread Disaster 1.28: NAS in 1999: Fierce Marketing but Fewer New Products 1.29: R&D Highlights: Science in Society 1.30: Products for 2000: Developing Drugs That Stand Out From the Crowd
Part II: INDUSTRY OVERVIEW
2.1: MARKET DATA 2.1.1: World Pharmaceutical Market, 1998 2.1.2: Top Ten Pharmaceutical Markets, 1998 2.1.3: Pharmaceutical Sales in 12 Leading Markets, 1998 2.1.4: Pharmaceutical Sales in 12 Leading Markets, 1998/99 2.1.5: World Pharmaceutical Market by Therapy Class, 1998 2.1.6: World Pharmaceutical Sales by Therapeutic Category, 1998 2.1.7.: Pharmaceutical Sales in 12 Markets by Therapeutic Category, 1998/99 2.1.8: Forecast for the Global Pharmaceutical Market, 1998 - 2002 2.1.9: Forecast for Worldwide Sales of 25 Leading Drugs, 1998 - 2002 2.1.10: Global Pharmaceutical Industry Growth, 1999 - 2004 2.1.11: Pharmaceutical Sales Growth in Europe and the US, 1998 2.1.12: Global OTC Market, 1998 - 2008 2.1.13: Worldwide Self-Medication Market by Region, 1998 2.1.14: Leading Therapeutic Categories in the Self-Medication Market, 1998 2.1.15: Worldwide Ethical Pharmaceutical Sales, 1998 2.1.16: Worldwide Market for Active Pharmaceutical Ingredients 2.1.17: Global Bulk Actives and Intermediates Market 2.1.18: Lowest-Cost Countries in the Life Sciences Sector, 1998 2.1.19: Market Value of Branded Pharmaceuticals for Children 2.1.20: Healthcare Expenditure in the G7 Countries, 1997
2.2: INDUSTRY DATA 2.2.1: Top 25 Pharmaceutical Companies Worldwide, 1998 2.2.2: Forecast for Pharmaceutical Companies' Growth 2.2.3: Pharmaceutical Companies in the Global FT500, 1998 2.2.4: Pharmaceutical Companies Ranked by Share Price Performance, 1998 2.2.5: Leading Pharmaceutical Groups by Market Capitalisation, 1998 - 1999 2.2.6: Fortune Magazine's Ranking of Pharmaceutical Companies, 1999 2.2.7: Pharmaceutical Industry Growth Rates, 1999 2.2.8: European/US Pharmaceutical Company Growth, 1999 2.2.9: Comparative US and European Pharmaceutical Industry Data, 1986 - 1997 2.2.10: Worldwide Pharmaceutical and Biotech Expenditure on Contract Services 2.2.11: Market Share of Various Outsourcing Companies, 1999 2.2.12: Number of Biotechnology Companies in Europe and the US 2.2.13: Biotech Stocks in the US and the UK, 1998 2.2.14: Biotech Companies Trading Below Cash Value, 1998 2.2.15: Equity Biotech Financing, 1997 - 1998 2.2.16: Merger and Acquisition Activity in the Biotechnology Industry, 1998 - 1999
2.3: R&D 2.3.1: Pharmaceutical Companies' R&D Expenditure, 1998 2.3.2: Top 25 Companies by Number of R&D Products, 1998 - 1999 2.3.3: Worldwide R&D Projects by Therapeutic Category, 1998/99 2.3.4: Forecast for Worldwide Pharmaceutical and Biotech R&D Expenditure, 1999 2.3.5: Pharmaceutical R&D Outsourcing Strategies, 1994 - 1999
2.4: MISCELLANEOUS 2.4.1: Strategies for Protecting Patented Drugs 2.4.2: Growth in the Bulk Active Material Market, 1998 - 2005 2.4.3: Number of Applications for Protection Certificates in the European Economic Area 2.4.4: Global Problems of Medicine Access 2.4.5: Regulatory Issues in Emerging Pharmaceutical Markets 2.4.6: National Incentives for the Development of the Biotech Sector 2.4.7: Average Cost of New Chemical Entity Development 2.4.8: NCEs Registered for Tropical Diseases, 1975 - 1997 2.4.9: Implications of Drug Donations to Poor Countries 2.4.10: Drug Candidates for Compulsory Licensing, 1999 2.4.11: World Bank Loans to the Middle East and North Africa, to 1998 2.4.12: Chiral Product Sales, 1998 2.4.13: UN Foundation Grants, 1999 2.4.14: Ten Leading Causes of Mortality in WHO Member Countries, 1998 2.4.15: WHO Forecast for the Global Disease Burden to 2030 2.4.16: The World Health Organisation's Working Budget, 2000/01 2.4.17: World Health Organisation Drug Disposal Guidelines, 1999
Part III: THERAPEUTICS
3.1: ALIMENTARY/METABOLIC Crohn's Disease 3.1.1: Worldwide Prevalence of Crohn's Disease 3.1.2: Incidence of Fistulae in Crohn's Disease Patients
Diabetes 3.1.3: Worldwide Diabetes Market, 1995 - 2025 3.1.4: Prevalence of Diabetes, 1997 - 2010 3.1.5: World Market for Insulin 3.1.6: Market Forecast for Type 2 Diabetes, 1999 - 2006 3.1.7: Prevalence of Type 2 Diabetes in the Western World 3.1.8: The Role of Prandial Glucose Regulators in the Treatment of Diabetes 3.1.9: Incidence of Substantial Insulin Resistance in Diabetics 3.1.10: Worldwide Market for Diabetic Foot Ulcers 3.1.11: Prevalence of Neuropathy in Diabetics 3.1.12: Use of Diabetic Pen Devices in the US and Europe 3.1.13: Prevalence of Major Hypoglycaemia in Diabetics
Hepatitis 3.1.14: Worldwide Prevalence of the Hepatitis B Virus 3.1.15: Worldwide Prevalence of Hepatitis C 3.1.16: Worldwide Interferon Market
Irritable Bowel Syndrome 3.1.17: Prevalence of Irritable Bowel Syndrome 3.1.18: Irritable Bowel Syndrome Market Forecast to 2005
Obesity 3.1.19: Worldwide Obesity Market Value 3.1.20: Worldwide Obesity Market Forecast to 2005
Miscellaneous 3.1.21: Worldwide Market for Gastro-Oesophageal Reflux Disease 3.1.22: Worldwide Dyspepsia Market 3.1.23: Co-Existence of Dyspepsia and Helicobacter pylori Infection 3.1.24: Advanced-Stage Kidney Disease Survival Rate 3.1.25: Worldwide Cost of Ulcer Treatment 3.1.26: Worldwide Incidence of Diarrhoea 3.1.27: Worldwide Market for Inflammatory Bowel Disease 3.1.28: Worldwide Market for Protein Wasting Diseases 3.1.29: Incidence of Hybrenoma 3.1.30: Worldwide Cases of Acute Renal Failure Associated with IGIVs, 1981 - 1999
3.2: BLOOD AND CLOTTING Haemophilia 3.2.1: Worldwide Prevalence of Haemophilia A 3.2.2: Proportion of Inhibitor Patients in the Haemophiliac Population
Septic Shock 3.2.3: Septic Shock Mortality Rate
Miscellaneous 3.2.4: Worldwide Statin Market Potential 3.2.5: Incidence of Von Willebrand Disorder 3.2.6: Market Potential for HIT and HITTS 3.2.7: Prevalence of Intradialytic Hypotension in Haemodialysis Patients 3.2.8: Potential Market for Virus Inactivation in Red Blood Concentrates 3.2.9: Blood Donation in the Americas 3.2.10: Prevalence of Haemolytic Uraemic Syndrome in North America
3.3: CANCER Brain Tumours 3.3.1: Market for the Treatment of Brain Metastases
Breast Cancer 3.3.2: Breast Cancer Treatment 3.3.3: Use of High-Dose Chemotherapy in Breast Cancer 3.3.4: Treatment of Premenopausal Breast Cancer 3.3.5: Risk of Breast Cancer Diagnosis in Women Under 50 3.3.6: Risk of Breast Cancer Associated with Atypical Hyperplasia or Lobular Carcinoma in situ 3.3.7: Prevalence of Node-Negative Breast Cancer in Newly Diagnosed Cases 3.3.8: Use of Selective Oestrogen Receptor Modulators in Breast Cancer Prevention 3.3.9: Risk of Breast Cancer in Women with the BRCA2 Gene
Cervical Cancer 3.3.10: Treatment of Cervical Cancer
Leukaemia 3.3.11: Prevalence of Chronic Myelogenous Leukaemia in the US and Western Europe 3.3.12: Prevalence of Chronic Lymphocytic Leukaemia in the US and Europe 3.3.13: Acute Myeloid Leukaemia: Disease Progression
Lung Cancer 3.3.14: Prevalence of Lung Cancer, 1999 - 2000
Prostate Cancer 3.3.15: Worldwide Market for Prostate Cancer Treatment, 1999 - 2006 3.3.16: Prevalence of Prostate Cancer, 1999 3.3.17: Prostate Cancer Mortality Rate, 1973 - 1996
Pancreatic Cancer 3.3.18: Pancreatic Cancer Survival Rates
Soft Tissue Sarcoma 3.3.19: Incidence of Soft Tissue Sarcoma in the US and Europe 3.3.20: Worldwide Prevalence of Soft Tissue Sarcoma of the Limbs
Miscellaneous 3.3.21: Prevalence of Breakthrough Cancer Pain in Western Europe and the US 3.3.22: Overexpression of the HER-2 Receptor in Cancer Patients 3.3.23: Gastric Cancer Mortality Rate 3.3.24: Incidence of Head and Neck Cancer in the US and Europe 3.3.25: Incidence of Colorectal Cancer Metastasis to the Liver in North America and Europe 3.3.26: Non-Hodgkin's Lymphoma: Forms and Treatment
3.4: CARDIOVASCULAR Cardiac 3.4.1: Worldwide Cardiovascular Disease Mortality Rate 3.4.2: Rate of Coronary Heart Disease, 1980s - 1990s 3.4.3: Worldwide Prevalence of Decompensated Heart Failure 3.4.4: Use of ACE-Inhibitors and Beta-Blockers in Treatment of Heart Failure 3.4.5: Heart Failure Population Forecast in the US and Europe, 2000
Hypertension 3.4.6: Worldwide Hypertension Market Value 3.4.7: Prevalence of Hypertension in the Western World 3.4.8: International Hypertension Guidelines, 1999 3.4.9: Rate of Non-Compliance in Patients on Oral Antihypertensives 3.4.10: Incidence of Dilated Cardiomyopathy in Europe and the US
Surgery 3.4.11: Open Heart Surgery Interventions in Europe and North America
Miscellaneous 3.4.12: Increased Incidence of Cardiovascular Events in Diabetics 3.4.13: Use of Antiplatelet Agents in Cardiac Disorders
3.5: DERMATOLOGICAL 3.5.1: Worldwide Prevalence of Psoriasis 3.5.2: Traumatic Burns Market 3.5.3: Incidence of SJS and TEN
3.6: GENITOURINARY Contraception 3.6.1: Worldwide Market for Contraceptive Products 3.6.2: Potential Market for a Reversible Male Contraceptive
Urological 3.6.3: Prevalence of Incontinence 3.6.4: Urinary Incontinence Market 3.6.5: Incidence of Vesicoureteral Reflux in Children
Sexual Dysfunction 3.6.6: Prevalence of Female Sexual Dysfunction 3.6.7: Causes of Erectile Dysfunction 3.6.8: Worldwide Market for Topical Erectile Dysfunction Therapies
Miscellaneous 3.6.9: Prevalence of Bacterial Vaginosis 3.6.10: Worldwide Incidence of Genital Chlamydia Infection 3.6.11: Prevalence of Hypogonadotrophic Hypogonadism 3.6.12: Prevalence of Cervical Dystonia in the US and Europe
3.7: HORMONAL 3.7.1: Prevalence of Acromegaly in the Western World
3.8: IMMUNOLOGICAL HIV/AIDS 3.8.1: Global Rate of HIV Infection, 1999 3.8.2: Global Prevalence of HIV 3.8.3: Worldwide Prevalence of HIV Subtype C 3.8.4: Prevalence of AIDS in the Americas 3.8.5: Annual Incidence of HIV-Infection in Babies 3.8.6: Annual Incidence of Paediatric HIV-1-Infection 3.8.7: HIV-1 Seroprevalence Among Childbearing Women 3.8.8: Global Impact of HIV/AIDS on Business
Transplantation 3.8.9: Treatments for the Prevention of Organ Transplant Rejection 3.8.10: Non-Compliance in Transplant Recipients 3.8.11: Incidence of Severe Graft Versus Host Disease in Unrelated Donor Transplants
Miscellaneous 3.8.12: Prevalence of Pemphigus Vulgaris 3.8.13: Prevalence of Hereditary Angioedema in the Western World 3.8.14: Worldwide Prevalence of Systemic Lupus Erythematosus
3.9: INFECTIOUS DISEASES General 3.9.1: Global Prevalence of Major Infectious Diseases, 1998 3.9.2: Global Mortality due to Infectious Disease
Helicobacter pylori Infection 3.9.3: Worldwide Prevalence of Helicobacter pylori Associated Disorders 3.9.4: Cost of Treating Helicobacter pylori Infections
Leprosy 3.9.5: Global Prevalence of Leprosy, 1999 - 2005
Malaria 3.9.6: Worldwide Incidence of Malaria 3.9.7: Worldwide Prevalence of Malaria 3.9.8: Worldwide Research Funding for Malaria
Meningitis 3.9.9: Worldwide Prevalence of Meningitis 3.9.10: Pneumococcal Meningitis Mortality Rate 3.9.11: Worldwide Prevalence of Lymphomatous Meningitis
Nosocomial Infections 3.9.12: Worldwide Incidence of Nosocomial Infections 3.9.13: Incidence of Nosocomial Device-Related Bloodstream Infections
Polio 3.9.14: Global Strategy for the Eradication of Polio
Tuberculosis 3.9.15: Worldwide Prevalence of Tuberculosis
Miscellaneous 3.9.16: Worldwide Antibiotic Market Value 3.9.17: Prevalence of Otitis Media in Children Under Three 3.9.18: Prevalence of Chlamydia Bacterial Infection 3.9.19: Prevalence of Onychomycosis 3.9.20: Worldwide Antibiotic Treatment for Respiratory Tract Infections 3.9.21: Worldwide Incidence of Hantavirus 3.9.22: Worldwide Antifungal Market, 1998 3.9.23: Worldwide Prevalence of Shigellosis 3.9.24: Worldwide Incidence of Bubonic Plague 3.9.25: Incidence of Glandular Fever in the US and Europe 3.9.26: Incidence of Influenza in the US, Europe and Japan 3.9.27: Cases of Measles in the Americas, 1997 - 1998 3.9.28: Prevalence of Clostridium difficile in North America 3.9.29: Importance of Mucosal Immunisation 3.9.30: Mortality in Developing Countries due to Rotavirus Associated Diarrhoea 3.9.31: Paediatric Mortality due to Pneumococcal Disease 3.9.32: Mortality due to Tetanus in Developing Countries, 1998
3.10: MUSCULOSKELETAL Arthritis 3.10.1: Worldwide Prevalence of Osteoarthritis 3.10.2: Worldwide Prevalence of Rheumatoid Arthritis 3.10.3: Treatments for Rheumatoid Arthritis 3.10.4: New Approaches to Rheumatoid Arthritis Treatment 3.10.5: Worldwide Prevalence of Psoriatic Arthritis
Inflammatory Disorders 3.10.6: Nimesulide-Associated Adverse Drug Reactions, 1985 - 1999
Osteoporosis 3.10.7: Severe Osteoporosis Market 3.10.8: Worldwide Hip Fracture Market, 1999 - 2050
Miscellaneous 3.10.9: Prevalence of Pompe's Disease in the Western World 3.10.10: Worldwide Muscle Relaxant Market
3.11: NEUROLOGICAL General 3.11.1: Worldwide Prevalence of Mental Disorders, 1998 - 2020
Alzheimer's Disease 3.11.2: Prevalence of Alzheimer's Disease in the Over 65 Population 3.11.3: Prevalence of Behavioural Problems in Alzheimer's Patients 3.11.4: Worldwide Forecast for Alzheimer's Disease, 2000
Anxiety 3.11.5: Prevalence of Generalised Anxiety Disorder
Depression 3.11.6: Worldwide Antidepressant Market, 1998 3.11.7: Treatment of Depression 3.11.8: Worldwide Market for Selective Serotonin Re-Uptake Inhibitors 3.11.9: New Approaches to Antidepressant Research & Development 3.11.10: Prevalence of Bipolar Disorders 3.11.11: Treatments for Bipolar Disorders
Multiple Sclerosis 3.11.12: Worldwide Prevalence of Multiple Sclerosis 3.11.13: Worldwide Market for Multiple Sclerosis Drugs 3.11.14: Multiple Sclerosis Disease Pattern
Parkinson's Disease 3.11.15: Worldwide Prevalence of Parkinson's Disease 3.11.16: Global Market Value of Parkinson's Disease 3.11.17: Rate of Dopaminergic-Related Psychosis in Parkinson's Patients
Schizophrenia 3.11.18: Worldwide Prevalence of Schizophrenia
Stroke 3.11.19: Worldwide Incidence of Stroke
Miscellaneous 3.11.20: Worldwide Analgesics Market Value 3.11.21: Prevalence of Attention Deficit Hyperactivity Disorder in Children 3.11.22: Prevalence of Migraine in School-Age Children 3.11.23: Market Potential for Insomnia 3.11.24: Market Value of Severe Head Trauma 3.11.25: Retirement Rate due to Essential Tremor 3.11.26: Worldwide Prevalence of Prion Diseases 3.11.27: Prevalence of Status Epilepticus 3.11.28: Global Smoking Cessation Market, 1999
3.12: PARASITIC 3.12.1: Malaria Cases Caused by Plasmodium falciparum 3.12.2: Incidence of Visceral Leishmaniasis in the Developing World
3.13: RESPIRATORY Allergy 3.13.1: Non-Sedating Antihistamine Market, 1998 - 1999 3.13.2: Association Between Allergic Rhinitis and Asthma
Asthma 3.13.3: Worldwide Prevalence of Asthma 3.13.4: Possible Causes of Asthma in Children 3.13.5: Worldwide Research Funding for Asthma 3.13.6: Use of Metered Dose Inhalers for Asthma 3.13.7: Use of Nebulisers for Anti-Asthma Drug Delivery 3.13.8: Worldwide Sales of Albuterol, 1998
Cystic Fibrosis 3.13.9: World Market for Cystic Fibrosis Therapies
Respiratory Infections 3.13.10: Worldwide Prevalence of Respiratory Syncytial Virus 3.13.11: Prevalence of Childhood Respiratory Syncytial Virus 3.13.12: RSV-Related Hospitalisations in Children Under Two Years
Miscellaneous 3.13.13: Global Prevalence of Chronic Obstructive Pulmonary Disease 3.13.14: Worldwide Prevalence of Congenital Alpha1-Antitrypsin Deficiency
3.14: SENSORY 3.14.1: Worldwide Prevalence of Blindness, 1999 - 2020 3.14.2: Prevalence of Age-Related Macular Degeneration 3.14.3: Worldwide Prevalence of Trachoma 3.14.4: Worldwide Prevalence of Glaucoma 3.14.5: Prevalence of Choroidal Neovascularisation
3.15: MISCELLANEOUS 3.15.1: World Market for Drug Delivery Systems 3.15.2: Disability-Adjusted Life Years Lost Worldwide due to Health Problems, 1999 3.15.3: Smoking-Related Deaths Worldwide, 1995 - 2030 3.15.4: Worldwide Surgical Adhesion Market Value 3.15.5: Global Birth Data 3.15.6: Global Use of Metered Dose Inhalers, 1999 - 2000 3.15.7: CFC-Free Metered Dose Inhaler Guidelines, 1999 3.15.8: Paediatric Mortality due to Disease in the Americas 3.15.9: Worldwide Herbal Medicines Market, 1999 - 2003 3.15.10: Annual Incidence of Digoxin Toxicity in the US and Europe 3.15.11: Implications of Unsafe Injection Practices
Part IV: COMPANIES
4.1: ABBOTT Financial Data 4.1.1: Abbott's Financial Data, 1998
Product Sales 4.1.2: Abbott's Leading Products, 1998 - 1999
R&D 4.1.3: Highlights of Abbott's R&D Pipeline
4.2: AMERICAN HOME PRODUCTS Financial Data 4.2.1: American Home Products' Financial Data, 1998 4.2.2: American Home Products' Sales by Division, 1998
Product Sales 4.2.3: American Home Products' Sales Forecast for Key Products, 1998 - 2001 4.2.4: American Home Products' Sales Forecast, 1999 - 2004
R&D 4.2.5: American Home Products' Late-Stage Product Pipeline
4.3: AMGEN Financial Data 4.3.1: Amgen's Financial Data, 1998
R&D 4.3.2: Highlights of Amgen's R&D Pipeline
4.4: ASTRAZENECA Financial Data 4.4.1: AstraZeneca's Pro Forma Financial Data, 1998 4.4.2: Losec/Prilosec Patent Expiry Dates
Regional Data 4.4.3: AstraZeneca's US Sales, 1998
R&D 4.4.4: Highlights of AstraZeneca's Oncology R&D Pipeline 4.4.5: Highlights of AstraZeneca's Cardiovascular Pipeline 4.4.6: Highlights of AstraZeneca's Gastrointestinal R&D Pipeline 4.4.7: Highlights of AstraZeneca's Respiratory Pipeline 4.4.8: Highlights of AstraZeneca's Pain Control R&D Pipeline 4.4.9: Highlights of AstraZeneca's CNS Pipeline 4.4.10: AstraZeneca's Development Projects 4.4.11: New Chemical Entities in AstraZeneca's R&D Pipeline
ASTRA Financial Data 4.4.12: Astra's Financial Data, 1998
Product Sales 4.4.13: Sales of Astra's Top Ten Products, 1998
ZENECA Financial Data 4.4.14: Zeneca's Financial Data, 1998 4.4.15: Zeneca's Pharmaceutical Sales by Leading Product, 1998
4.5: AVENTIS Financial Data 4.5.1: Aventis' Pro Forma Sales, 1998 - 1999
Regional Sales 4.5.2: Aventis' Japanese Pro Forma Sales, 1999
HOECHST MARION ROUSSEL Financial Data 4.5.3: Hoechst's Financial Data, 1998
Regional Data 4.5.4: Hoechst Marion Roussel's Sales by Region, 1998
Product Sales 4.5.5: Hoechst Marion Roussel's Leading Product Sales, 1998 4.5.6: Sales Forecast for Arava, 2002/03 4.5.7: Worldwide Use of Norplant
R&D 4.5.8: Hoechst Marion Roussel's R&D Expenditure, 1998
RH�NE-POULENC RORER Financial Data 4.5.9: Rh�ne-Poulenc's Financial Data, 1998 4.5.10: Rh�ne-Poulenc's Sales by Division, 1998 4.5.11: Rh�ne-Poulenc's Pharmaceutical Sales, 1998
Regional Data 4.5.12: Rh�ne-Poulenc Rorer's Sales by Region, 1998 4.5.13: Rh�ne-Poulenc Rorer Japan's Sales, 1998
Product Sales 4.5.14: Rh�ne-Poulenc's Leading Product Sales, 1998 4.5.15: Rhone-Poulenc's New Product Sales, 1998
4.6: BASF Financial Data 4.6.1: BASF's Financial Data, 1998 4.6.2: BASF's Sales by Business Segment, 1998
Regional Data 4.6.3: BASF Pharma's Sales by Region, 1998 4.6.4: BASF Pharma's German Sales, 1995 - 1998
Product Sales 4.6.5: BASF's Leading Pharmaceutical Products, 1998
R&D 4.6.6: BASF Pharma's R&D Expenditure, 1998 4.6.7: BASF Pharma's R&D Pipeline 4.6.8: BASF's Late-Stage Development Pipeline 4.6.9: BASF's Active Pharmaceutical Ingredients Sales, 1998
4.7: BAYER Financial Data 4.7.1: Financial Data, 1998 4.7.2: Bayer Healthcare Results, 1997 - 1998
Regional Data 4.7.3: Bayer Yakuhin's Financial Data, 1998 4.7.4: Highlights of Bayer's Japanese R&D Pipeline 4.7.5: Bayer's Pharmaceutical Sales in the UK and Ireland, 1998 4.7.6: Bayer's Sales in the Philippines, 1998 4.7.7: Bayer's Sales in Turkey, 1998
Product Sales 4.7.8: Bayer's Leading Products by Sales, 1998
4.8: BOEHRINGER INGELHEIM Financial Data 4.8.1: Boehringer Ingelheim's Financial Data, 1998 4.8.2: Boehringer Ingelheim's Sales by Division, 1998
Regional Data 4.8.3: Boehringer Ingelheim's Sales by Region, 1998 4.8.4: Boehringer Ingelheim's OTC Sales by Region, 1998 4.8.5: Boehringer Ingelheim's Japanese Pharmaceutical Sales, 1997 - 1998
Product Sales 4.8.6: Boehringer Ingelheim's Sales by Product, 1998 4.8.7: Boehringer Ingelheim's OTC Sales by Therapeutic Class, 1998 4.8.8: Prescriptions for Pramipexole in the US, 1998
R&D 4.8.9: Boehringer Ingelheim's NCE pipeline 4.8.10: Highlights of Boehringer Ingelheim's R&D Pipeline
4.9: BRISTOL-MYERS SQUIBB Financial Data 4.9.1: Bristol-Myers Squibb's Financial Data, 1998 4.9.2: Bristol-Myers Squibb's Sales by Division, 1998
Regional Data 4.9.3: Bristol-Myers Squibb's Sales by Region, 1998
Product Sales 4.9.4: Bristol-Myers Squibb's Leading Products, 1998 4.9.5: Sales of Paclitaxel, 1998
4.10: FUJISAWA Financial Data 4.10.1: Fujisawa's Financial Data, 1999 4.10.2: Fujisawa's Sales by Business Segment, 1999 4.10.3: Fujisawa's Sales by Product Category, 1999
Regional Data 4.10.4: Fujisawa's Sales by Region, 1999
Product Sales 4.10.5: Fujisawa's Leading Product Sales, 1999
4.11: GLAXO WELLCOME Financial Data 4.11.1: Glaxo Wellcome's Financial Data, 1998 4.11.2: Glaxo Wellcome's Sales by Therapeutic Category, 1998
Regional Data 4.11.3: Glaxo Wellcome's Sales by Region, 1998 4.11.4: Glaxo Wellcome's Regional Sales Analysis, 1998 4.11.5: Glaxo Wellcome KK's Sales, 1998 4.11.6: Glaxo Wellcome's Forecast for Growth in Malaysia, 1999 4.11.7: Glaxo Wellcome's Egyptian Revenues 4.11.8: US Sales of Troglitazone, 1998 4.11.9: Potential Chinese Market for Zeffix
Product Sales 4.11.10: Glaxo Wellcome's Sales by Leading Product, 1998
R&D 4.11.11: Highlights of Glaxo Wellcome's Late Stage Development Pipeline, 1999
4.12: JOHNSON & JOHNSON Financial Data 4.12.1: Johnson & Johnson's Financial Data, 1998 4.12.2: Johnson & Johnson's Sales by Business Segment, 1998
4.13: LILLY Financial Data 4.13.1: Lilly's Financial Data, 1998 4.13.2: Lilly's Sales Forecast, 1999 - 2004
Regulation 4.13.3: Lilly's Japanese Sales, 1998
Product Sales 4.13.4: Lilly's Leading Product Sales, 1998 4.13.5: Worldwide Use of Prozac 4.13.6: Sales Forecast for Actos
R&D 4.13.7: Highlights of Lilly's R&D Pipeline
4.14: MERCK & CO Financial Data 4.14.1: Merck & Co's Financial Data, 1998 4.14.2: Merck's Earnings Growth Forecast, 2000 4.14.3: Merck 's Sales by Therapeutic Category, 1998
Regional Data 4.14.4: Merck's Sales by Region, 1998 4.14.5: Merck-Medco's Drug Expenditure, 1998
Product Sales 4.14.6: Merck's Leading Product Sales, 1998 4.14.7: Merck's Patent Expiries, 2000 - 2002 4.14.8: Merck's Patent Expiries to 2005
R&D 4.14.9: Highlights of Merck's Late Stage R&D Pipeline 4.14.10: Merck 's Forecast for R&D Expenditure, 2000 4.14.11: Highlights of Merck's Near-Term R&D Pipeline
4.15: MERCK KGAA Financial Data 4.15.1: Merck KGaA's Financial Data, 1998 4.15.2: Merck KGaA's Sales by Division, 1998
Regional Data 4.15.3: Merck KGaA's Sales by Region, 1998
Product Sales 4.15.4: Merck KGaA's Leading Product Sales, 1998
4.16: MONSANTO Financial Data 4.16.1: Monsanto's Financial Data, 1998 4.16.2: Monsanto's Sales by Division, 1998 4.16.3: Monsanto's Sales by Region, 1998
Corporate 4.16.4: Monsanto and Pharmacia & Upjohn Merger
4.17: NOVARTIS Financial Data 4.17.1: Novartis' Financial Data, 1998 4.17.2: Novartis' Sales by Division, 1998
Regional Data 4.17.3: Novartis' Sales by Region, 1998 4.17.4: Novartis' Japanese Pharmaceutical Sales, 1998 4.17.5: Novartis' South Korean Sales
Product Sales 4.17.6: Novartis' Leading Product Sales, 1998 4.17.7: Annual Sales of Neoral
R&D 4.17.8: Highlights of Novartis' R&D Pipeline 4.17.9: Novartis' Major Launches, 1999 - 2002 4.17.10: Novartis' Key NCE launches, 2000/2001
4.18: NOVO NORDISK Financial Data 4.18.1: Novo Nordisk's Financial Data, 1998 4.18.2: Novo Nordisk's Healthcare Sales, 1998 4.18.3: Novo Nordisk's Sales, 1999 - 2000 4.18.4: Novo Nordisk's Operating Profit Forecast, 1998 - 1999 4.18.5: Novo Nordisk's Sales by Business Segment, 1998 4.18.6: Novo Nordisk's Sales by Therapeutic Category, 1998
Regional Data 4.18.7: Novo Nordisk's Sales by Region, 1998
4.19: PFIZER Financial Data 4.19.1: Pfizer's Financial Data, 1998 4.19.2: Pfizer's Sales by Division, 1998 4.19.3: Pfizer's Sales Forecast, 1999 - 2004
Regional Data 4.19.4: Pfizer's Sales by Region, 1998 4.19.5: Pfizer's Japanese Sales, 1997 - 1998 4.19.6: Pfizer's German Sales, 1998
Product Sales 4.19.7: Pfizer's Leading Product Sales, 1998 4.19.8: Worldwide Use of Viagra 4.19.9: Suspected Adverse Reactions to Pfizer's Viagra in the UK, 1998/99 4.19.10: Worldwide Sales of Norvasc
R&D 4.19.11: Highlights of Pfizer's Near-Term Product Pipeline 4.19.12: Highlights of Pfizer's Japanese R&D Pipeline
4.20: PHARMACIA & UPJOHN Financial Data 4.20.1: Pharmacia & Upjohn's Financial Data, 1998 4.20.2: Pharmacia & Upjohn's Sales by Business Category, 1998
Regional Data 4.20.3: Pharmacia & Upjohn's Sales by Region, 1998
Product Sales 4.20.4: Pharmacia & Upjohn's Leading Product Sales, 1998 4.20.5: Prescriptions for Pramipexole in the US, 1998
R&D 4.20.6: Highlights of Pharmacia & Upjohn's R&D Pipeline
Corporate 4.20.7: Pharmacia & Upjohn and Monsanto Merger
4.21: ROCHE Financial Data 4.21.1: Roche's Financial Data, 1998 4.21.2: Roche's Sales by Division, 1998
Regional Data 4.21.3: Roche's Sales by Region, 1998 4.21.4: Nippon Roche's Pharmaceutical Sales, 1998 4.21.5: Highlights of Roche's Japanese R&D Pipeline
Product Sales 4.21.6: Roche's Leading Product Sales, 1998 4.21.7: Roche's Sales by Product, 1998 4.21.8: Worldwide Sales of Carvedilol, 1998 4.21.9: Roche's Vitamin Sales, 1998 4.21.10: Market for Ticlid, 1998
R&D 4.21.11: Highlights of Roche's Late-Stage Development Pipeline 4.21.12: Roche's Late-Stage Product Pipeline 4.21.13: Highlights of Roche's Late Development Pipeline
4.22: SANKYO Financial Data 4.22.1: Sankyo's Financial Data, 1998
Product Sales 4.22.2: Sankyo's Leading Product Sales, 1998
4.23: SANOFI-SYNTH�LABO Financial Data 4.23.1: Sanofi-Synth�labo's Financial Data, 1998 4.23.2: Sanofi and Synth�labo's Profit Growth, 1998
R&D 4.23.3: Highlights of Sanofi-Synth�labo's Japanese Product Pipeline
SANOFI 4.23.4: Sanofi's Financial Data, 1998 4.23.5: Sanofi's Leading Product Sales, 1998 4.23.6: Sanofi's Sales by Division, 1998
SYNTH�LABO 4.23.7: Synth�labo's Financial Data, 1998 4.23.8: Synth�labo's Sales by Division, 1998 4.23.9: Synth�labo's Sales by Region, 1998 4.23.10: Synth�labo's Leading Product Sales, 1998 4.23.11: Synth�labo's R&D Expenditure, 1998
4.24: SCHERING AG Financial Data 4.24.1: Schering AG's Financial Data, 1998 4.24.2: Schering's Forecast for 1999 4.24.3: Schering's Growth Forecast, 1999 - 2005 4.24.4: Schering's Sales by Business Sector 4.24.5: Schering's Sales by Therapeutic Category, 1998
Regional Data 4.24.6: Schering's Sales by Region, 1998
Product Sales 4.24.7: Schering's Leading Product Sales, 1998 4.24.8: Worldwide Sales of Triquilar, 1998
4.25: SCHERING-PLOUGH Financial Data 4.25.1: Schering-Plough's Financial Data, 1998 4.25.2: Schering-Plough's Sales by Division, 1998
Regional Data 4.25.3: Schering-Plough's Sales by Region, 1998
Product Sales 4.25.4: Schering-Plough's Leading Product Sales, 1998 4.25.5: Sales of Rebetron, 1998 - 2002 4.25.6: Sales Forecast for Claritin, 1999
R&D 4.25.7: Schering-Plough's R&D Budget, 1999 4.25.8: Highlights of Schering-Plough's R&D Pipeline 4.25.9: Schering-Plough's Phase III Development Projects
4.26: SHIONOGI Financial Data 4.26.1: Shionogi's Financial Data, 1999
Product Sales 4.26.2: Shionogi's Leading Product Sales, 1999
4.27: SMITHKLINE BEECHAM Financial Data 4.27.1: SmithKline Beecham's Financial Data, 1998 4.27.2: SmithKline Beecham's Aims, 1999 - 2002 4.27.3: SmithKline Beecham's Sales by Division, 1998
Regional Data 4.27.4: SmithKline Beecham's Sales by Therapeutic Category, 1998 4.27.5: SmithKline Beecham's Brazilian Market Share, 1999 4.27.6: SmithKline Beecham's Thai Sales, 1998
Product Sales 4.27.7: SmithKline Beecham's Pharmaceutical Sales Analysis, 1998 4.27.8: SmithKline Beecham's Leading Product Sales, 1998
4.28: TAKEDA Financial Data 4.28.1: Takeda's Financial Data, 1999 4.28.2: Takeda's Sales by Division, 1999
Regional Data 4.28.3: Takeda's Sales by Region, 1999
Product Sales 4.28.4: Takeda's Leading Product Sales, 1999 4.28.5: Sales Forecast for Takeda Products
4.29: WARNER-LAMBERT Financial Data 4.29.1: Warner-Lambert's Financial Data, 1998 4.29.2: Warner-Lambert's Sales by Division, 1998 4.29.3: Warner-Lambert's Sales Forecast, 1999 4.29.4: Warner-Lambert's Sales Forecast, 1999 - 2004
Regional Data 4.29.5: Warner-Lambert's Pharmaceutical Sales by Region, 1998
Product Sales 4.29.6: Warner-Lambert's Leading Product Sales, 1998 4.29.7: Warner-Lambert's Leading OTC Product Sales, 1998 4.29.8: Sales of Rezulin, 1998
R&D 4.29.9: Warner-Lambert's R&D Budget, 1999 4.29.10: Highlights of Warner-Lambert's R&D Pipeline
4.30: YAMANOUCHI Financial Data 4.30.1: Yamanouchi's Financial Data, 1999 4.30.2: Yamanouchi's Sales by Division, 1999 4.30.3: Yamanouchi's Sales by Region, 1999
Product Sales 4.30.4: Yamanouchi's Leading Product Sales, 1999
INDEX
CONTENTS - Volume 2
5.1: AFRICA General 5.1.1: Cases of Meningitis in Africa, 1996 - 1999 5.1.2: Prevalence of HIV in Sub-Saharan Africa 5.1.3: Incidence of HIV Infection in Sub-Saharan Africa 5.1.4: Prevalence of Onchocercal Infection in West Africa, 1974 - 1999 5.1.5: Number of Guinea Worm Cases in Africa
Algeria 5.1.6: Algerian Pharmaceutical Imports, 1998 5.1.7: Annual Pharmaceutical Expenditure in Algeria
Egypt 5.1.8: Egyptian Pharmaceutical Market, 1998 5.1.9: Egyptian Pharmaceutical Industry
Morocco 5.1.10: Prevalence of Trachoma in Morocco
Namibia 5.1.11: Namibian Medicines Budget, 1998 - 2000
Nigeria 5.1.12: Nigerian Healthcare Budget, 1999 5.1.13: Counterfeit Medicines in Nigeria 5.1.14: Immunisation Coverage in Nigeria, 1994 - 1999 5.1.15: Cases of HIV in Nigeria
South Africa 5.1.16: Average Discount for South African Wholesalers, 1998/99 5.1.17: Prevalence of HIV in South Africa 5.1.18: Annual Incidence of Neonatal HIV in South Africa 5.1.19: South African Budget for AIDS, 1999 5.1.20: Cost of Triple Therapy AIDS Drugs in South Africa 5.1.21: South African Clinical Research Market, 1999 - 2002
Tanzania 5.1.22: Incidence of Trachoma in Tanzania
Uganda 7 5.1.23: Forecast for Healthcare Access in Uganda 5.1.24: Incidence of HIV in Uganda
5.2: AMERICA - NORTH Canada Market Data 5.2.1: Canadian Pharmaceutical Market, 1998 5.2.2: PMAC Member Companies' Sales and Expenditure, 1997 - 1998 5.2.3: Canadian Generic Drug Sales, 1997 - 1998 5.2.4: Canadian Branded Pharmaceutical Market, 1997 - 1998 5.2.5: Canadian Prescriptions by Region, 1998 5.2.6: Leading Therapeutic Classes in Canada, 1998 5.2.7: Top 20 Dispensed Drugs in Canada, 1998 5.2.8: Top Selling Prescription Drugs in Canada, 1998 5.2.9: Fastest Growing Prescription Drugs in Canada, 1998
Industry Data 5.2.10: Canadian Expenditure on R&D, 1999 - 2000 5.2.11: Leading Pharmaceutical Companies in Canada, 1998 5.2.12: Canadian Biotechnology Sector
Regulation 5.2.13: Pharmaceutical Expenditure in Canada, 1998/99
Therapeutic Data 5.2.14: Incidence of Foot Ulcers in Canadian Diabetics 5.2.15: Incidence of Hepatitis A in Canada, 1992 - 1996 5.2.16: Prevalence of Hepatitis C in Canada 5.2.17: Canadian Thrombolytic Market 5.2.18: Incidence of Bladder Cancer in Canada 5.2.19: Annual Incidence of Heart Attack in Canada 5.2.20: Number of Abortions in Canada, 1995 5.2.21: Prevalence of Erectile Dysfunction in Canada 5.2.22: Prevalence of Social Anxiety Disorder in Canada 5.2.23: Incidence of Pertussis in Canada 5.2.24: Prevalence of Cystic Fibrosis in Canada
United States of America Market Data 5.2.25: US Drug Expenditure, 1998 5.2.26: Leading Products in the US, 1998 5.2.27: Leading US Products by Worldwide Sales, 1998 5.2.28: Top Selling US Drugs Launched in 1998 5.2.29: Pharmaceutical Sales Growth in the US, 1999 5.2.30: Forecast for Pharmaceutical Sales in the US, 1999 5.2.31: US Pharmaceutical Market Forecast, 1999 - 2003 5.2.32: US Prescription Market Value 5.2.33: Leading Products by Prescription in the US, 1998 5.2.34: Growth Rates of Prescription Pharmaceuticals in the US, 1997/98 5.2.35: US Prescription Drug Sales by Distribution Channel, 1997/98 5.2.36: US OTC Market Value 5.2.37: US Self-Medication Market, 1998 5.2.38: Generic vs Brand Breakdown of US Pharmaceutical Sales, 1997 - 1998 5.2.39: Generic Product Sales in the US, 1988 - 1998 5.2.40: Number of OTC Products Available in the US 5.2.41: US Outpatient Prescription Drug Expenditure, 1985 - 1997 5.2.42: Potential for Generic Substitution in the US Outpatient Market 5.2.43: Number of Pharmacies in the US 5.2.44: Healthcare Expenditure in the US, 1997 5.2.45: Retail Prescriptions Dispensed in the US, 1998/99 5.2.46: Retail Prescription Drug Sales Forecast in the US, 1999 5.2.47: US Prescriptions Paid for by Managed Care Organisations, 1995 - 1998 5.2.48: Use of the Internet for Health and Medical Information in the US, 1998 5.2.49: Annual Number of Prescriptions for the Elderly in the US
Industry Data 5.2.50: US Pharmaceutical Company Financial Results, 1998 5.2.51: Leading Companies by US Drug Sales, 1998 5.2.52: Leading Companies by Prescriptions Dispensed in the US, 1998 5.2.53: Leading Pharmaceutical Companies by Prescriptions Dispensed in the US, 1998 5.2.54: Pharmaceutical Companies in the US FT500, 1998 5.2.55: R&D Expenditure in the US, 1998 - 1999 5.2.56: US Pharmaceutical R&D Expenditure, 1990 - 1999 5.2.57: Major US Companies' R&D Expenditure, 1997 - 1999 5.2.58: Sales by Research-Based Companies in the US, 1998 - 1999 5.2.59: Top Ten US Generics Companies by Market Share, 1996 -1998 5.2.60: US Drugstore Mark-Ups for Generics 5.2.61: Top 10 US Companies by DTC Advertising Expenditure, 1998/99 5.2.62: Top 10 DTC Advertised Brands in the US, 1998/99 5.2.63: US Pharmaceutical Industry Promotional Activity, 1997 5.2.64: Top Ten Spending DTC Brands in the US, 1997 - 1998 5.2.65: US Biotechnology Industry Data, 1998 5.2.66: US Biotech Sector Share Price Performance, 1998 5.2.67: US Biotech Stock Performance, 1998 5.2.68: US Biotech 100 Market Capitalisation, 1998 5.2.69: Burn Rate of US Biotech Companies 5.2.70: US Biotechnology Stock Market Sector, 1998 5.2.71: US Public Biotech Sector, 1998 5.2.72: Biotech Products Approved in the US, 1998 5.2.73: Forecast for the US Biotechnology Industry, 1999 5.2.74: Prescription Drug Expenditure for US Managed Care Firms, 1999 5.2.75: Cost of DTC Television Advertising 5.2.76: US Industry Losses due to Pakistan's Intellectual Property Laws
Regulation 5.2.77: FDA New Product Approvals, 1998 5.2.78: FDA Approvals, 1998 5.2.79: Expected New Product Launches in the US, 1999 - 2002 5.2.80: FDA Budget, 2000 5.2.81: Key US Patent Expiries, 2000 - 2005 5.2.82: Approval Times for Abbreviated New Drug Applications in the US 5.2.83: Safety-Related NME Withdrawals by the FDA, 1994 - 1998 5.2.84: Number of Generic Drugs Approved by the OGD, 1998 5.2.85: Annual Cost of the US Medicare Programme
Therapeutic Data Alimentary/Metabolic 5.2.86: US Diabetes Market Value 5.2.87: Prevalence of Diabetes in the US 5.2.88: Prevalence of Type 2 Diabetes in the US, 1999 - 2025 5.2.89: Use of Pumps in the Treatment of Diabetes Type 1 in the US 5.2.90: Prevalence of Peripheral Neuropathy in the US 5.2.91: Prevalence of Diabetic Gastroparesis in the US 5.2.92: Hospitalisations and Mortality due to Chronic Liver Disease in the US 5.2.93: Prevalence of Hepatitis C in the US 5.2.94: Prevalence of Gastro-Oesphageal Reflux Disease in the US 5.2.95: Incidence of Kidney Disease in the US 5.2.96: Prevalence of Familial Polyposis in the US 5.2.97: Prevalence of Gout in the US 5.2.98: Incidence of Ulcers in the US 5.2.99: US Market for Anti-Obesity Drugs, 1999 - 2005 5.2.100: Proton Pump Inhibitor Market in the US 5.2.101: Incidence of Chronic Renal Failure in Children in the US
Blood and Clotting 5.2.102: Prevalence of Haemophilia in the US 5.2.103: Prevalence of Hypercholesterolaemia in the US 5.2.104: Cholesterol-Lowering Drug Market in the US 5.2.105: Prevalence of Von Willebrand's Disease in the US 5.2.106: Incidence of Nitric Oxide-Induced Shock in the US 5.2.107: Annual Number of Stent Placements in the US 5.2.108: Incidence of Ticlopidine-Associated TTP in the US 5.2.109: US Generic Warfarin Market 5.2.110: Associated Cholesterol and Triglycide Levels in Patients with Dyslipidaemia in the US
Cancer 5.2.111: Prevalence of Brain Cancer in the US 5.2.112: Incidence of Breast Cancer in the US 5.2.113: Number of US Women at High Risk of Breast Cancer 5.2.114: Prevalence of Metastatic Breast Cancer in the US 5.2.115: Market for Anti-Oestrogen Breast Cancer Treatments in the US 5.2.116: Incidence of Cervical Cancer in the US, 1998 5.2.117: Mortality due to Metastatic Colon Cancer in the US 5.2.118: Incidence of Colorectal Cancer in the US 5.2.119: Incidence of Gastric Cancer in the US 5.2.120: Incidence of Head and Neck Cancer in the US 5.2.121: Prevalence of Acute Myeloid Leukaemia in the US 5.2.122: Prevalence of Low-Grade Non-Hodgkin's Lymphoma in the US 5.2.123: Incidence of Cutaneous T-cell Lymphoma in the US 5.2.124: Incidence of Non-Small-Cell Lung Cancer in the US, 1999 5.2.125: Incidence of Ovarian Cancer in the US 5.2.126: Prevalence of Pancreatic Cancer in the US 5.2.127: Annual Incidence of Prostate Cancer in the US 5.2.128: Prevalence of Skin Cancer in the US 5.2.129: Incidence of Basal Cell Carcinoma in the US 5.2.130: Incidence of Melanoma in the US 5.2.131: Number of Patients Receiving Radiation Therapy in the US 5.2.132: Prevalence of Renal Cell Carcinoma in the US 5.2.133: Prevalence of Amyloidosis in the US
Cardiovascular 5.2.134: Prevalence of Heart Failure in the US 5.2.135: Prevalence of Congestive Heart Failure in the US 5.2.136: Prevalence of Atrial Fibrillation in the US 5.2.137: Incidence of Unstable Angina in the US 5.2.138: Prevalence of Hypertension in the US 5.2.139: Incidence of Refractory Myocardial Ischaemia 5.2.140: US ACE-inhibitor Prescription Market, 1998 5.2.141: Annual Number of Coronary Artery Bypass Grafts Performed in the US
Dermatological 5.2.142: Prevalence of Scleroderma in the US 5.2.143: Prevalence of Psoriasis in the US 5.2.144: Female Facial Hair Removal in the US
Genitourinary 5.2.145: Prevalence of Irritable Bowel Syndrome in the US 5.2.146: Prevalence of Urge Incontinence in the US 5.2.147: Prevalence of Urinary Tract Infections in the US 5.2.148: Incidence of Genital Warts in the US 5.2.149: Prevalence of Herpes Virus Type II in the US 5.2.150: Prevalence of Benign Prostatic Hyperplasia in the US 5.2.151: US Incidence of Cervical Dysplasia 5.2.152: Incidence of Unintended Pregnancy in the US 5.2.153: Annual Number of Assisted Reproduction Cycles Started in the US 5.2.154: Prevalence of Female Sexual Dysfunction in the US
Hormonal 5.2.155: Prevalence of Growth Hormone Deficiency in the US 5.2.156: US Market for Secondary Hyperparathyroidism 5.2.157: Prevalence of Male Hypogonadism in the US 5.2.158: Potential US Market for Testosterone Replacement Therapy
Immunological 5.2.159: US Transplant Market 5.2.160: Annual Number of Bone-Marrow Transplants in the US 5.2.161: Incidence of Acute Rejection of Kidney Transplants in the US 5.2.162: Resistant Strains of HIV in Treatment-Na�ve Patients in the US 5.2.163: US Protease Inhibitor Market Growth, 1999 5.2.164: Number of Perinatal AIDS Cases in the US, 1992 - 1997 5.2.165: Prevalence of Sj�gren's Syndrome in the US 5.2.166: Prevalence of Systemic Lupus Erythematosus in the US 5.2.167: Cyclosporin Market in the US
Infectious Diseases 5.2.168: Prevalence of Influenza in the US 5.2.169: US Market Projections for Influenza Drugs, 1999/2000 5.2.170: Prevalence of Type B in American Influenza Strains 5.2.171: US Antifungal Market 5.2.172: Cost of Antibiotic-Resistant Infections in the US 5.2.173: Prevalence of Group A Streptococcus Infections in the US 5.2.174: Rate of Resistance to Streptococcus Pneumoniae in the US 5.2.175: US Incidence of Enterohaemorragic E Coli Infection 5.2.176: Incidence of Severe Meningococcaemia in the US 5.2.177: Incidence of Campylobacter Diarrhoea in the US 5.2.178: Hospitalisations and Mortality due to Rotavirus in the US 5.2.179: US Mortality due to Rotavirus in Young Children 5.2.180: Neonate Mortality Following Hepatitis B Vaccination in the US, 1991 - 1999 5.2.181: Number of US Doctor Visits as a Result of Ear Infections 5.2.182: Incidence of Pneumococcal Meningitis in US College Students
Musculoskeletal 5.2.183: Impact of Osteoarthritis in the US 5.2.184: Prevalence of Rheumatoid Arthritis in the US 5.2.185: Prevalence of Psoriatic Arthritis in the US 5.2.186: US Osteoporosis Prevention Market 5.2.187: Prevalence of Osteoporosis in US Men 5.2.188: Prevalence of Duchenne Muscular Dystrophy in the US 5.2.189: US Muscle Relaxant Market 5.2.190: Annual Number of Hip Replacement Operations in the US 5.2.191: NSAI-Related Hospitalisations and Mortality in the US
Neurological 5.2.192: Prevalence of Social Anxiety Disorder in the US 5.2.193: Prevalence of Post-Traumatic Stress Disorder in the US 5.2.194: Incidence of Autism in the US 5.2.195: Prevalence of Attention Deficit Hyperactivity Disorder in the US 5.2.196: Prevalence of Epilepsy in the US 5.2.197: Prevalence of Motion Sickness in the US 5.2.198: US Migraine Market Value 5.2.199: Incidence of Multiple Sclerosis in the US 5.2.200: Prevalence of Narcolepsy in the US 5.2.201: Prevalence of Cataplexy in US Narcoleptics 5.2.202: Prevalence of Parkinson's Disease in the US 5.2.203: Prevalence of Post-Herpetic Neuralgia in the US 5.2.204: Prevalence of Restless Leg Syndrome in the US 5.2.205: US Market for Anti-Insomnia Therapies 5.2.206: Prevalence of Obstructive Sleep Apnoea in the US 5.2.207: US Smoking Cessation Data 5.2.208: Annual Incidence of Stroke in the US 5.2.209: Incidence of Trauma in the US
Parasitical 5.2.210: Prevalence of Lyme Disease in the US
Respiratory 5.2.211: Incidence of Respiratory Tract Infections in the US 5.2.212: Prevalence of Asthma in the US 5.2.213: Prevalence of Cystic Fibrosis in the US 5.2.214: US Market for Nasal Steroids 5.2.215: US Non-Sedating Antihistamine Market 5.2.216: Prevalence of Paediatric Allergic Rhinitis in the US 5.2.217: Prevalence of Respiratory Distress Syndrome in Premature Infants in the US
Sensory 5.2.218: Market Value of the US Prescription Ophthalmic Sector
Miscellaneous 5.2.219: US Adverse Drug Reaction Mortality Rate 5.2.220: Prevalence of Hypertension and Hyperlipidaemia in the US 5.2.221: Prescriptions for Pain Associated with Dental Procedures in the US 5.2.222: Incidence of Oleander Poisoning in the US, 1997 5.2.223: US Funeral Industry Value
5.3: AMERICA - CENTRAL AND SOUTH Latin America 5.3.1: Healthcare in Latin America 5.3.2: Latin American Pharmaceutical Market 5.3.3: Self-Medication Market in Latin America, 1998 5.3.4: Inappropriate Use of Antibiotics in Latin America 5.3.5: Incidence of HIV Infection in Latin America, 1999 5.3.6: South American Classification of OTC Medicines 5.3.7: Incidence of HIV Infection in Central America and the Caribbean, 1999
Argentina 5.3.8: Argentinian Pharmaceutical Market, 1998/99 5.3.9: Top 20 Argentinian Companies, 1998/99 5.3.10: Argentinian OTC Pharmaceutical Market, 1999 5.3.11: Argentinian Antirheumatics Market 5.3.12: Prevalence of Cystic Fibrosis in Argentina
Brazil 5.3.13: Brazilian Pharmaceutical Sales, 1995 - 1998 5.3.14: Brazilian Pharmaceutical Sales, 1999 - 2000 5.3.15: Brazilian Self-Medication Market, 1998 5.3.16: Finished Medicine Imports to Brazil, 1997 - 1999 5.3.17: Brazilian Pharmaceutical Market Leaders, 1998 5.3.18: Average Price of Medicines in Brazil, 1996 - 1998 5.3.19: Brazilian SUS Pharmaceutical Expenditure 5.3.20: Brazilian Generics Legislation, 1999 5.3.21: Brazilian Imports of Haemoderivatives 5.3.22: Brazilian Imports of Insulin, 1997 - 1998 5.3.23: Incidence of Chagas Disease in Brazil, 1980 - 1998
Chile 5.3.24: Chilean Pharmaceutical Market, 1998 5.3.25: Chilean Pharmaceutical Consumption, 1993 - 1999 5.3.26: Incidence of Chagas Disease in Chile, 1982 - 1998
Colombia 5.3.27: Colombian Pharmaceutical Market
Mexico 5.3.28: Mexican Pharmaceutical Market, 1998 5.3.29: Mexican OTC Market, 1998 5.3.30: Pharmaceutical Investment in Mexico, 1999 - 2004 5.3.31: Mexican Trade Data, 1998 - 1999
Peru 5.3.32: Peruvian Pharmaceutical Market
5.4: AUSTRALASIA Australia Market Data 5.4.1: Australian Pharmaceutical Sales Environment, 1998/99 5.4.2: Top 10 Pharmaceutical Products in Australia, 1998 5.4.3: Australian Pharmaceutical Trade Data, 1998/99
Industry Data 5.4.4: Australian Pharmaceutical Industry Data 5.4.5: Australian Pharmaceutical Industry Turnover, 1998/99 5.4.6: Top 20 Pharmaceutical Companies in Australia, 1998 5.4.7: Australian Pharmaceutical R&D, 1999 5.4.8: The Australian Pharmaceutical Industry Investment Programme, 1999 5.4.9: Average Australian Research Grant 5.4.10: Pharmacist Mark-ups in Australia 5.4.11: Australian Pharmaceutical Firms' Philanthropic Activities, 1998/99
Regulation 5.4.12: Australian Government Pharmaceutical Expenditure, 1996 - 2020 5.4.13: Australian Government Pharmaceutical Expenditure, 1998 5.4.14: Australian Pharmaceutical Benefits Scheme Data, 1997/98 5.4.15: Australian Pharmaceutical Benefits Scheme Data, 1998/99 5.4.16: Australian PBS Expenditure by Leading Therapeutic Category, 1998/99 5.4.17: Australian Government Expenditure on the HSDP, 1998/99 5.4.18: New Medicines Approved in Australia, 1998 5.4.19: New Product Approvals in Australia, 1998 5.4.20: Australian Medicines Approved for New Uses/Combinations, 1998 5.4.21: Australian Therapeutic Goods Administration Fees, 1998 - 1999 5.4.22: Prescription Fraud in Australia
Therapeutic Data 5.4.23: Cost of ADR-Related Hospital Admissions in Australia
New Zealand Regulation 5.4.24: New Zealand Medicine Tender Awards, 1999
Therapeutic Data 5.4.25: Prevalence of Severe Acne in New Zealand 5.4.26: Prevalence of Heart Failure in New Zealand 5.4.27: Prescription of Subsidised Statin Products in New Zealand 5.4.28: Prevalence of Asthma in New Zealand 5.4.29: MS Patients Eligible for Beta-Interferon Treatment in New Zealand, 1999
Oceania 5.4.30: Incidence of Leprosy in Papua New Guinea, 1969 - 1999 5.4.31: Forecast for the Eradication of Polio in the Western Pacific, 1999
5.5: EUROPE Market Data 5.5.1: European Pharmaceutical Expenditure, 1997 - 1999 5.5.2: European OTC Market, 1995 - 1999 5.5.3: European Market for Biotechnology Products, 2005 5.5.4: European Market for Non-Prescription Pain Relief Products, 1999 - 2003 5.5.5: European Pharmaceutical Packaging Market, 1999 - 2009
Industry Data 5.5.6: Pharmaceutical Companies in the European FT500, 1998 5.5.7: Major European Companies' R&D Expenditure Forecast, 1999 5.5.8: Ten Best Performing European Pharmaceutical Companies, 1998/99 5.5.9: Ten Best Performing European Pharmaceutical Companies, 1994 - 1999 5.5.10: European Medicines Evaluation Agency Activities, 1998 5.5.11: EC Mutual Recognition Approval Procedures, 1998 5.5.12: European Applications for Supplementary Protection Certificates, 1998 5.5.13: Withdrawals of Centralised Approval Applications in the EU, 1998 5.5.14: Number of Vaccines in the EC Centralised Procedure, 1995 - 1999 5.5.15: Activities of the Economic and Social Committee
Therapeutic Data 5.5.16: European Cost of Diabetes by Country 5.5.17: Prevalence of Crohn's Disease in Europe 5.5.18: Prevalence of Hepatitis C in Europe 5.5.19: Prevalence of Hepatitis B in the EU 5.5.20: Incidence of Breast Cancer in Europe 5.5.21: Incidence of Gastric Cancer in Europe 5.5.22: Incidence of Non-Small-Cell Lung Cancer in the EU 5.5.23: Incidence of Ovarian Cancer in the EU 5.5.24: Early Diagnoses of Prostate Cancer in Europe 5.5.25: Incidence of Malignant Melanoma in the EU 5.5.26: Incidence of Soft Tissue Sarcoma in Europe 5.5.27: Incidence of Heart Failure in Europe 5.5.28: European Skin Care Market, 1993 - 1998 5.5.29: Market for Surgical Sealants in Europe 5.5.30: Prevalence of Hypogonadotrophic Hypogonadism in the EU 5.5.31: Prevalence of Overactive Bladder in Europe 5.5.32: Market for Transplants in the EU 5.5.33: Number of Kidney Transplants in Europe, 1997 5.5.34: Incidence of Paediatric HIV/AIDS in Western Europe, 1997 5.5.35: Prevalence of CMV Retinitis in Europe, 1998 5.5.36: Market for Cyclosporin in Europe, 1998 5.5.37: Incidence of Vertebral Fracture in the Over-50s in Europe 5.5.38: Treatment Costs of Osteoporosis-Related Fractures in Europe 5.5.39: European Use of Atypical Antipsychotic Drugs 5.5.40: Tobacco-Related Disease in Europe, 1999 - 2020 5.5.41: Annual Number of Smoking-Related Deaths in the EU, 1999 - 2025
Belgium 5.5.42: Cost of Annual Levy to the Belgian Pharmaceutical Industry, 1998 5.5.43: Number of Patients on Dialysis in Belgium
Central And Eastern Europe General 5.5.44: OTC Sales in Central and Eastern Europe, 1994 - 2003 5.5.45: Drug Donation to Central and Eastern Europe 5.5.46: Electronic Submission of MA Applications in CEE, 1996 - 1999 5.5.47: Central and Eastern European Medicines Approval Process, 1999
Albania 5.5.48: Drug Donation to Albania, 1999
Bulgaria 5.5.49: Bulgarian Pharmaceutical Market
Croatia 5.5.50: Pharmaceutical Expenditure in Croatia, 1995 - 1997
Czech Republic 5.5.51: Czech Pharmaceutical Market, 1998 5.5.52: Leading Therapeutic Categories in the Czech Pharmaceutical Market, 1998 5.5.53: Leading Pharmaceutical Companies in the Czech Republic, 1998 5.5.54: Marketing Authorisation Approval Times in the Czech Republic
Hungary 5.5.55: Hungarian Pharmaceutical Market, 1998 5.5.56: Hungarian Healthcare Costs, 1998 5.5.57: Leading Therapeutic Categories in the Hungarian Pharmaceutical Market, 1998 5.5.58: Hungarian OEP Pharmaceutical Budget, 1999 5.5.59: Hungarian Drug Reimbursement Budget, 1999 5.5.60: Generic Drug Manufacture in Hungary 5.5.61: Leading Pharmaceutical Companies in Hungary, 1998 5.5.62: Prevalence of HIV in Hungary 5.5.63: Hungarian Accession to the EU
Poland 5.5.64: Polish Pharmaceutical Sales, 1998 5.5.65: Polish Self-Medication Market, 1998
Romania 5.5.66: Romanian Pharmaceutical Market, 1998 5.5.67: Leading Therapeutic Categories in the Romanian Pharmaceutical Market, 1998 5.5.68: Leading Pharmaceutical Companies in Romania, 1998 5.5.69: Incidence of HIV/AIDS in Romania
Slovak Republic 5.5.70: Slovak Pharmaceutical Market, 1998 5.5.71: Leading Therapeutic Categories in the Slovak Pharmaceutical Market, 1998 5.5.72: Leading Pharmaceutical Companies in the Slovak Republic, 1998
France Market Data 5.5.73: French Pharmaceutical Sales, 1998 5.5.74: Number of Prescriptions Written in France, 1998 5.5.75: French Generics Market, 1998 - 1999 5.5.76: French Generics Market 5.5.77: French Generic Retail Market, 1998 - 2002 5.5.78: French Amoxicillin Market, 1995 - 1998
Industry Data 5.5.79: French Pharmaceutical Industry Data, 1993 - 1999 5.5.80: French Independent Pharmaceutical Companies' Market Share, 1998 - 1999 5.5.81: French Pharmaceutical Industry Contributions, 1998 5.5.82: French Generics Industry Rankings, 1999 5.5.83: Market Share of the Top Five Wholesalers in France, 1998 5.5.84: French Pharmacists' Gross Margins, 1990 - 1999 5.5.85: French Pharmaceutical Distribution Costs, 1998 5.5.86: Pharmaceutical Promotional Expenditure in France
Regulation 5.5.87: French Pharmaceutical Expenditure, 1998/99 5.5.88: French Target Rates for Medical Expenditure, 1999 5.5.89: French Healthcare Expenditure, 1998 5.5.90: French Community Healthcare Expenditure Target, 1999 5.5.91: French Healthcare Expenditure Budget, 2000 5.5.92: French Healthcare Insurance Expenditure, 1998 5.5.93: Review of Pharmaceutical Products in France, 1998 5.5.94: New French Health Agencies, 1999 5.5.95: Adverse Effect Warnings on French Pharmaceutical Products 5.5.96: French State Expenditure on Human Genome Research, 2000 - 2005
Therapeutic Data 5.5.97: Type 2 Diabetes in France: Prevalence and Costs 5.5.98: Hepatitis B Vaccination Rates in France, 1996 - 1998 5.5.99: Hepatitis C Treatment in France, 1997 5.5.100: French Market for Vein Tonics, 1983 - 1999 5.5.101: Haemophilia and HIV Infection in France in the 1980s 5.5.102: Rate of Therapeutic Failure in French HIV Patients 5.5.103: Annual Number of Smoking-Related Deaths in France, 1999 - 2025 5.5.104: Nicotine Patch Use in France, 1993 - 1995
Germany Market Data 5.5.105: German Pharmaceutical Market, 1998 5.5.106: German Prescription Market Value, 1998 5.5.107: German Non-Hospital Prescription Sales, 1997 5.5.108: Growth of Highly Innovative Products in Germany, 1992 - 1998 5.5.109: Average German Household Expenditure on Healthcare, 1996 - 1998
Industry Data 5.5.110: German Pharmaceutical Industry Forecast, 1999 5.5.111: Pharmaceutical Wholesalers' German Market Share, 1998 5.5.112: Parallel Imports in Germany, 1998
Regulation 5.5.113: Krankenkassen Pharmaceutical Expenditure, 1998 5.5.114: Krankenkassen Pharmaceutical Expenditure, 1992 - 1998 5.5.115: Krankenkassen Budget, 2000 5.5.116: Pharmaceutical Costs per Head by Regional Krankenkassen, 1998 5.5.117: German Reference Price Changes, 1999 5.5.118: German Science Budget, 1999 5.5.119: German Healthcare Reform Legislation, 1999 5.5.120: Cost of Captopril Products to the German Krankenkassen 5.5.121: Pharmaceutical Budget Breakdown for Hamburg, 1998
Therapeutic Data 5.5.122: Prevalence of Chronic Hepatitis B and C in Germany 5.5.123: Number of People Requiring Renal Dialysis in Germany, 1999 5.5.124: Increased Incidence of Type 2 Diabetes in Germany, 1999 and 2009 5.5.125: German Urology Market 5.5.126: Prevalence of Erectile Dysfunction in Germany 5.5.127: Prevalence of HIV in Germany 5.5.128: Prevalence of Alzheimer's Disease in Germany 5.5.129: Prevalence of Multiple Sclerosis in Germany 5.5.130: Post-Hospitalisation Medication in Germany, 1998
Italy 5.5.131: Italian Pharmaceutical Market Value 5.5.132: Italian State Pharmaceutical Expenditure, 1998 5.5.133: Italian Pharmaceutical Expenditure, 1998/99 5.5.134: Italian Pharmaceutical Budget Overshot, 1998 - 1999 5.5.135: Forecast for Italian Pharmaceutical Expenditure, 1999 - 2000 5.5.136: Italian Increase in VAT on Medicines, 1997 5.5.137: Italian Expenditure on Non-Reimbursed Prescription Products 5.5.138: Mortality Due to Cardiovascular Disease in Italy, 1998
The Netherlands Market Data 5.5.139: Dutch Pharmaceutical Market, 1998 - 1999 5.5.140: Prescriptions of Analgesics in the Netherlands, 1998 5.5.141: Dutch Pharmaceutical Sales, 1998
Regulation 5.5.142: Dutch Regulatory Activities, 1998 - 1999 5.5.143: Dutch Pharmaceutical Prices, 1995 - 1998 5.5.144: Pharmaceutical Reimbursement in the Netherlands 5.5.145: Forecast for Dutch Pharmaceutical Reimbursement, 2000 5.5.146: Dutch Patient Co-Payments on Pharmaceuticals, 1999 5.5.147: Most Frequent ADRs in the Netherlands, 1998 5.5.148: Most Frequent ADRs in the Netherlands by Product, 1998 5.5.149: Pharmacy Claw-Back in the Netherlands, 1999 - 2000
Portugal Market Data 5.5.150: Pharmaceutical Sales in Portugal, 1998 5.5.151: Leading Pharmaceutical Product Sales in Portugal, 1998 5.5.152: Leading Pharmaceutical Product Sales in Portugal, 1997 5.5.153: Portuguese Pharmaceutical Sales by Therapeutic Category, 1998 5.5.154: Portuguese OTC Market, 1998 5.5.155: Medicines on the Portuguese Market, 1998 5.5.156: Portuguese Generics Market
Industry Data 5.5.157: Top 20 Pharmaceutical Companies by Sales to the Portuguese SNS, 1998 5.5.158: Top 20 Pharmaceutical Companies by Sales to the Portuguese SNS, 1997 5.5.159: Number of Pharmaceutical Companies in Portugal, 1998 5.5.160: Portuguese Hospital Debt to Pharmaceutical Companies, 1998/99
Regulation 5.5.161: Portuguese Health Service Pharmaceutical Expenditure, 1992 - 1999 5.5.162: Portuguese Pharmaceutical Approvals, 1998 5.5.163: Applications for Reimbursement Status in Portugal, 1996 - 1998 5.5.164: Portuguese Regulatory Authority Inspections, 1998 5.5.165: Portuguese Adverse Drug Reaction Reports, 1998 5.5.166: Reimbursement Changes in Portugal, 1999
Scandinavia Denmark 5.5.167: Pharmaceutical Cost of Top Ten Diagnoses in Denmark 5.5.168: Cost of Top Ten Pharmaceutical Products in Denmark 5.5.169: Danish Pharmaceutical Expenditure, 1998 5.5.170: Pharmaceutical Reimbursement in Denmark, 1998 5.5.171: Danish Medicine Reimbursement, 2000 5.5.172: Danish Macrolide Use, 1998/99 5.5.173: Use of Third-Generation Contraceptive Pills in Denmark, 1984 - 1993
Finland 5.5.174: Finnish Pharmaceutical Market, 1998 5.5.175: Finnish Pharmaceutical Sales, 1998 5.5.176: Finnish OTC Sales, 1998 5.5.177: Finland's Pharmaceutical Exports by Market, 1998 5.5.178: Finnish Pharmaceutical Sales by Therapeutic Category, 1999 5.5.179: Top Selling Products in Finland, 1999 5.5.180: Finnish Ex-Factory Pharmaceutical Prices 5.5.181: Leading Pharmaceutical Companies in Finland, 1998 5.5.182: Finnish Wholesale Prices, 1998 5.5.183: Mutual Recognition Procedure Approvals in Finland, 1995 - 1998 5.5.184: Finnish Reimbursement Listings, 1999 - 2000 5.5.185: Finnish Prescription Fraud, 1998
Norway 5.5.186: Norwegian Pharmaceutical Market, 1998 5.5.187: Norwegian Pharmaceutical Sales, 1998 5.5.188: Top Selling New Substances in Norway, 1998 5.5.189: Leading Prescription Sales in Norway, 1998 5.5.190: Leading Norwegian Prescription Sales at Wholesale Prices, 1998
Sweden 5.5.191: Swedish Pharmaceutical Sales, 1998 5.5.192: Leading Companies in Sweden by Sales, 1998 5.5.193: Swedish Pharmaceutical Budget, 1998 - 1999 5.5.194: Swedish Regulatory Financial Data, 1998 5.5.195: Swedish Pharmaceutical Benefits Cost by Region, 1998 5.5.196: Prescription Medicine Sales in Sweden, 1998 5.5.197: Marketing Applications for New Chemical Entities in Sweden, 1997 - 1998 5.5.198: Cost of Losec to the Swedish Health Service, 1998 5.5.199: Cost of Obesity in Sweden 5.5.200: Cost of Impotence in Sweden, 1998 5.5.201: Incidence of Multiple Sclerosis in Sweden 5.5.202: Prevalence of Exfoliative Glaucoma in Sweden
Spain Market Data 5.5.203: Spanish Pharmaceutical Market, 1998 5.5.204: Spanish Pharmaceutical Data, 1998 5.5.205: Spanish OTC Sales, 1998 5.5.206: Spanish Pharmaceutical Expenditure by Therapeutic Category, 1997 - 1998 5.5.207: Spanish Generics Market, 1996 - 2001
Industry Data 5.5.208: Outstanding Debts in the Spanish Pharmaceutical Payment Chain, 1998 - 1999 5.5.209: Annual Industry Contribution to the Spanish Pharmaceutical Budget
Regulation 5.5.210: Spanish Pharmaceutical Expenditure, 1998 5.5.211: Spanish Pharmaceutical Expenditure Target, 1999 5.5.212: Spanish Pharmaceutical Expenditure by Regional Authority, 1998 - 1999 5.5.213: Spanish State Healthcare Funding, 1999 5.5.214: Spanish Pharmaceutical Prices, 1996 - 1999 5.5.215: Average Price Cut on Medicines in Spain, 1999 5.5.216: Spanish Medicines Agency Fees, 1999 5.5.217: Spanish Medicines Agency Budget, 1999 5.5.218: Prescription Fraud in Spain, 1994 - 1998 5.5.219: Spanish Hospital Sales through Tenders 5.5.220: Spanish Adverse Drug Reaction Reports, 1998 5.5.221: Annual Abortion Rate in Spain 5.5.222: Incidence of AIDS in Spain, 1994 - 1999 5.5.223: Prevalence of HIV in Spain, 1999
Switzerland 5.5.224: Annual Cost of Obesity in Switzerland 5.5.225: Prevalence of Arthritis in Switzerland 5.5.226: Prevalence of Relapsing-Remitting Multiple Sclerosis in Switzerland
United Kingdom Market Data 5.5.227: The Pharmaceutical Market in the UK 5.5.228: UK Self-Medication Market 5.5.229: Healthcare Expenditure in the UK, 1998
Industry Data 5.5.230: UK Pharmaceutical Production Data, 1998-99 5.5.231: UK Pharmaceutical R&D Expenditure, 1998 5.5.232: Cost of Parallel Imports to the UK Pharmaceutical Industry 5.5.233: Number of Sales Rep Visits to GPs in the UK, 1998 5.5.234: Cost of Industry Non-Compliance with the PPRS 5.5.235: The UK Biopharmaceutical Sector, 1996 - 1999 5.5.236: UK Biotechnology Industry Data, 1998 5.5.237: UK Biotech Sector Share Price Change, 1998 5.5.238: Biotech Employment in Scotland, 1994 - 1999 5.5.239: Barriers to Development in the UK Biotechnology Sector
NHS Data 5.5.240: UK NHS Drugs Expenditure, 1997/98 5.5.241: NHS Expenditure on Prescriptions, 1998 5.5.242: NHS Prescription Expenditure Breakdown, 1998 5.5.243: UK Prescription Charge Revenue, 1999 - 2000 5.5.244: UK Prescriptions for the Elderly 5.5.245: NHS Expenditure on Pharmaceuticals, 1969 - 1998 5.5.246: UK Prescription Data, 1997/98 -1998/99 5.5.247: English Health Authority Variation in Prescribing, 1998/99 5.5.248: Forecast for the NHS Deficit, 1999 5.5.249: UK Healthcare Plans, 1999 5.5.250: UK Government Health Aims, 1999 - 2010 5.5.251: UK Pharmacies' Turnover, 1950 - 1970 5.5.252: Prescriptions Dispensed as a Proportion of Pharmacy Turnover, 1970 - 1999 5.5.253: Breakdown of Prescriptions in England by Indication, 1993 - 1999 5.5.254: NHS Sales by the British Generics Manufacturers' Assocation, 1998 5.5.255: Generic Prescriptions in the UK, 1999 - 2002 5.5.256: Cost of Generic/Branded Prescriptions to the NHS 5.5.257: Generic Prescribing Rate for GPs in the UK, 1999 - 2002 5.5.258: Cost of GP Consultation to the NHS 5.5.259: NHS Cost of Hospital and GP Prescribing, 1997/98 5.5.260: Number of Dispensing Doctors in the UK, 1999 5.5.261: Annual Cost of Prescription Fraud to the NHS 5.5.262: Rate of Detected Fraud in the NHS, 1997 - 1999 5.5.263: Net Deficit for Health Authorities and Trusts in England and Wales, 1998/99 5.5.264: NHS Expenditure by Therapeutic Category 5.5.265: NHS Hospital Expenditure on Cancer Services in England 5.5.266: Cost of Cancer Products to the NHS, 1992 - 1998 5.5.267: UK Government Expenditure on Cytotoxics 5.5.268: Cardiovascular Prescribing in the UK, 1994 - 1999 5.5.269: NHS Expenditure on Impotence 5.5.270: NHS Expenditure on Pfizer's Viagra, 1998/99 5.5.271: Prescription of Antibiotics in the UK, 1995 -1998 5.5.272: Expected Cost of Influenza to the NHS, 1999/2000 5.5.273: Cost of Smoking-Related Diseases to the NHS 5.5.274: NHS Cost of Treating Smokers 5.5.275: Implications of UK Shift from Hospital to Primary Treatment, 1957 - 1999
Regulation 5.5.276: UK Medicines Control Agency's Activities, 1993 - 1998 5.5.277: UK Medicines Control Agency's Performance, 1997/98 5.5.278: UK Medicines Control Agency's Activities, 1998/99 5.5.279: MCA Operating Forecast, 2000 5.5.280: UK Prescription Medicines Code of Practice Authority Activities, 1998 5.5.281: UK Prescription Pricing Authority's Expenditure, 1998/99 5.5.282: UK's NICE Budget, 1999/2000 5.5.283: Dual-Named Substances in the UK 5.5.284: Allocations for Healthcare and Science in the UK 1999 Budget 5.5.285: Medicine Prices in the UK, 1989 - 1999 5.5.286: ADR Reports by UK Pharmacists 5.5.287: Yellow Card ADR Reports in the UK, 1994 - 1999 5.5.288: Number of NCEs Introduced in the UK, 1970 - 1998 5.5.289: UK Parallel Import Applications, 1998/99 5.5.290: Forecast for Generic Product Price Increases Due to Patient Packs in the UK 5.5.291: UK Medicines Trade Balance, 1998 5.5.292: Annual Cost of Resale Price Maintenance on Medicines in the UK
Therapeutic Data Alimentary/Metabolic 5.5.293: Prevalence of Diabetes in the UK 5.5.294: Prevalence of Diabetic Foot Ulcers in the UK 5.5.295: UK Obesity Market, 1980 - 1999
Blood and Clotting 5.5.296: Prevalence of Haemophilia B in the UK
Cancer 5.5.297: UK Cancer Mortality Rate, 1999 - 2010 5.5.298: Incidence of Breast Cancer in England and Wales 5.5.299: Annual Incidence of Colon Cancer in the UK 5.5.300: Annual Incidence of Gynaecological Cancer in the UK 5.5.301: Incidence of Ovarian Cancer in England and Wales 5.5.302: Incidence of Prostate Cancer in the UK 5.5.303: Use of Cytotoxic Products in the UK
Cardiovascular 5.5.304: Mortality Due to Heart Disease in the UK, 1995 - 2000 5.5.305: Cost of Acute Coronary Syndromes in the UK, 1998 5.5.306: Prevalence of Coronary Heart Disease in England 5.5.307: Prevalence of Angina in the UK 5.5.308: Cost of Statins in Heart Attack Prevention in the UK 5.5.309: Cases of Controlled Hypertension in the UK
Dermatological 5.5.310: Market for Scar Treatment in the UK
Genitourinary 5.5.311: UK Market for Benign Prostatic Hyperplasia 5.5.312: Prevalence of PMDD in the UK 5.5.313: Annual Abortion Rate in the UK 5.5.314: Number of Abortions in the UK, 1995 - 1997 5.5.315: Number of Oral Contraceptive Users in the UK, 1995 - 1999 5.5.316: Risk of Venous Thromboembolism in Oral Contraceptive Users 5.5.317: Oral Contraceptive Adverse Drug Reactions in the UK, 1989 - 1999 5.5.318: Hormone Replacement Therapy Prescription Charges in the UK, 1997 5.5.319: Rate of Smoking-Related Male Impotence in the UK 5.5.320: Prevalence of Bladder Problems in UK Adults Aged Over 40
Immunological 5.5.321: Prevalence of HIV in the UK, 1995 - 1998 5.5.322: Number of Live Births to HIV-Infected Mothers in the UK, 1997
Infectious Diseases 5.5.323: Incidence of Influenza in the UK 5.5.324: Prevalence of Meningitis in the UK, 1998 - 1999 5.5.325: Incidence of Rubella-Associated Births in the UK, 1970 - 1996 5.5.326: MMR Vaccination Rate in the UK 5.5.327: Reduction in UK Infection Rates due to Vaccination, 1999
Musculoskeletal 5.5.328: Prevalence of Osteoporosis in the UK 5.5.329: Non-Steroidal-Anti-Inflammatory Market in the UK
Neurological 5.5.330: Cost of Depression in the UK 5.5.331: Prevalence of Multiple Sclerosis in the UK 5.5.332: Treatment of Multiple Sclerosis in the UK 5.5.333: UK Deaths from New Variant Creutzfeldt-Jakob Disease, 1995 - 1999 5.5.334: UK Smoking Cessation Market, 1998 - 2002 5.5.335: Prevalence of Daily Fatigue in the UK
Respiratory 5.5.336: Prevalence of Asthma in the UK 5.5.337: Use of Metered Dose Inhalers by Asthmatics in the UK 5.5.338: Proportion of the UK Population Affected by Allergies
Miscellaneous 5.5.339: UK Hospital Admission Data, 1957 - 1999 5.5.340: Paracetamol-Associated Hospital Admissions in England, 1996 - 1998 5.5.341: Paediatric Use of Off-Label Medicines in UK Hospitals 5.5.342: Rate of Organ Donation in the UK, 1991 - 1998 5.5.343: Rates of Non-Compliance in Elderly Patients in the UK 5.5.344: Annual Cost of Antibiotics Prescribed by UK Dentists 5.5.345: Use of Animals in UK Scientific Procedures, 1998 5.5.346: UK Animal Research Data, 1996 - 1997
5.6: FAR EAST General 5.6.1: Asia-Pacific Pharmaceutical Market 5.6.2: Asia-Pacific Pharmaceutical Market, 1998 - 2003 5.6.3: Implications of the 1998 Asian Crisis for Pharmaceutical Markets 5.6.4: Prospects for Asian Pharmaceutical Recovery, 1999 5.6.5: Southeast Asia's Pharmaceutical Market Growth, 1999 - 2002 5.6.6: Asian Obesity Rates 5.6.7: Incidence of HIV Infection in Asia, 1999 5.6.8: Costs Due to Influenza in Southeast Asia 5.6.9: Asian Clinical Research Market 5.6.10: Prevalence of Tuberculosis in the Western Pacific 5.6.11: Prevalence of Hepatitis B in the Western Pacific
Cambodia 5.6.12: Cambodian Annual Healthcare Budget 5.6.13: Forecast for the Spread of HIV/AIDS in Cambodia, 1999 - 2006
China Market Data 5.6.14: Chinese Pharmaceutical Market Value, 1998 5.6.15: Chinese Pharmaceutical Market, 1990 - 1998 5.6.16: The Chinese Pharmaceutical Market, 1997 5.6.17: Chinese Prescription Market, 1998 - 1999 5.6.18: Leading Therapeutic Categories in China, 1998 5.6.19: Chinese OTC Market 5.6.20: Chinese Pharmaceutical Import Data, 1996 - 1999 5.6.21: Shanghai's Pharmaceutical Sector, 1998 5.6.22: Beijing's Pharmaceutical Sector, 1998 - 2010 5.6.23: Market for Western Prescription Products in China, 1998 - 2010 5.6.24: Provision of Free Medical Care and Labour Insurance in China
Industry Data 5.6.25: Leading Pharmaceutical Companies in China, 1998 5.6.26: Chinese Pharmaceutical Production, 1998 - 1999 5.6.27: Chinese Pharmaceutical Output, 1999 5.6.28: Chinese Pharmaceutical Product Surplus, 1998 5.6.29: Chinese Pharmaceutical Biotechnology Data, 1997 - 2014 5.6.30: Prescription Biotech Pharmaceutical Market in China, 1997 - 1999 5.6.31: Leading Chinese Pharmaceutical Joint-Ventures with Foreign Companies, 1999 5.6.32: Investments by PhRMA Member Companies in China
Regulation 5.6.33: Chinese Drug Expenditure, 1997 - 1998 5.6.34: Chinese Government's Healthcare Expenditure Forecast, 2010 5.6.35: Chinese Pharmaceutical Price/Profit Control 5.6.36: Chinese Accession to the World Trade Organisation 5.6.37: Health Expenditure Forecast for Tibet, 1999
Therapeutic Data 5.6.38: Prevalence of Hepatitis B in China 5.6.39: Hepatitis B Costs as a Proportion of Chinese Healthcare Expenditure 5.6.40: Prevalence of Sexually Transmitted Diseases in China, 1998 5.6.41: Prevalence of HIV in China, 1999 5.6.42: Annual Consumption of Norfloxacin in China 5.6.43: Prevalence of Arthritis in China 5.6.44: Chinese Migraine Market 5.6.45: Number of Smokers in China 5.6.46: Prevalence of Blindness in China, 1999 - 2020
Hong Kong 5.6.47: Drug Budget in Hong Kong, 1998 5.6.48: Forecast for Expenditure on Statins in Hong Kong, 1994 - 2000
Indonesia 5.6.49: Indonesian Pharmaceutical Market, 1999 5.6.50: Leading Foreign Pharmaceutical Companies in Indonesia, 1998/99 5.6.51: Indonesian Raw Material Imports 5.6.52: Prevalence of Erectile Dysfunction in Indonesia 5.6.53: Incidence of Influenza in Indonesia
East Timor 5.6.54: Healthcare Coverage in East Timor, 1999 5.6.55: Prevalence of Active Tuberculosis in East Timor, 1999
Japan Market Data 5.6.56: Pharmaceutical Production in Japan, 1997 5.6.57: Japanese Top Five Therapeutic Categories, 1997 5.6.58: Japanese Pharmaceutical Trade by Country, 1997 5.6.59: Penetration of Japanese Market by FDA-Approved Drugs, 1998 5.6.60: Forecast for Japanese Blockbuster Drug Peak Sales 5.6.61: Japanese Generic Market Value
Industry Data 5.6.62: Pharmaceutical Companies in the Japanese FT500, 1998 5.6.63: Top Ten Japanese Pharmaceutical Companies' Financial Results, 1999 5.6.64: Financial Forecast for Leading Japanese Companies, 2000 5.6.65: Outlook for Leading Japanese Pharmaceutical Companies 5.6.66: The Japanese Pharmaceutical Industry in the Global Context, 1999 5.6.67: Globalisation of Japanese Pharmaceutical Companies, 1997 5.6.68: Japanese Biotechnology Market, 1999 - 2010
Regulation 5.6.69: Japanese Healthcare Expenditure, 1998 5.6.70: Japanese Healthcare Expenditure, 1996 5.6.71: Pharmaceutical Patents Granted in Japan, 1997 5.6.72: Average Patent Life of Pharmaceuticals in Japan 5.6.73: Patent Life for Pharmaceuticals in Japan, 1999 5.6.74: Japanese Generic Reimbursement, 1999 5.6.75: Annual Japanese NCE Approval Rate 5.6.76: Japanese "Reasonable-Zone", 1992 - 1998
Therapeutic Data 5.6.77: Prevalence of Diabetes in Japan 5.6.78: Japanese Diuretic Market, 1998 5.6.79: Ticlopidine-Associated-TTP in Japan, 1996 - 1999 5.6.80: Prevalence of NSCLC in Japan 5.6.81: Prevalence of Breast Cancer in Japan 5.6.82: Prostate Cancer Mortality Rate in Japan, 1999 - 2015 5.6.83: Incidence of Liver Cancer in Japan 5.6.84: Incidence of Gastric Cancer in Japan 5.6.85: Prevalence of Fatal and Recurrent Arrhythmias in Japan 5.6.86: Prevalence of Hyperlipaemia in Japan, 1999 5.6.87: Prevalence of Psoriasis in Japan 5.6.88: Incidence of Acne in Japan 5.6.89: Japanese Prescription Anti-Acne Market 5.6.90: Japanese Market for Hair Loss Products 5.6.91: Prevalence of Impotence in Japan 5.6.92: Incidence of Endometriosis in Japan, 1997 5.6.93: Use of High-Dose Oral Contraceptives in Japan 5.6.94: Japanese Market for Low-Dose Oral Contraceptives 5.6.95: Number of Abortions in Japan, 1998 5.6.96: Incidence of HIV/AIDS in Japan, 1998 - 2003 5.6.97: Incidence of Oral Candidiasis in the Japanese HIV Population 5.6.98: Japanese Incidence of Tuberculosis, 1997 - 1999 5.6.99: Prevalence of Influenza in Japan 5.6.100: Japanese Prescription Market for Antifungals, 1999 5.6.101: Prevalence of Arthritis and Rheumatism in Japan 5.6.102: Japanese Market for Non-Steroidal Anti-Inflammatories 5.6.103: Japanese Anaesthetic Market, 1994 - 1999 5.6.104: Prevalence of Parkinson's Disease in Japan 5.6.105: Japanese Asthma Market 5.6.106: Incidence of Childhood Asthma in Japan, 1979 - 1999 5.6.107: Japanese Allergy Market, 1979 - 1999 5.6.108: Prevalence of Glaucoma in Japan 5.6.109: Japanese Market for Stress Nuclear Cardiac Imaging Products, 1998 5.6.110: Prevalence of Fabry Disease in Japan
Malaysia 5.6.111: Annual Malaysian Expenditure on Drug Imports 5.6.112: Prescribing/Dispensing Split in Malaysia 5.6.113: Risk of Japanese Encephalitis in Malaysia, 1999 5.6.114: Mortality due to Nipah Encephalitis in Malaysia, 1998/99
The Philippines 5.6.115: Generic Market Share in the Philippines 5.6.116: Branded Pharmaceutical Market in the Philippines 5.6.117: Incidence of Influenza in the Philippines
South Korea 5.6.118: South Korean Bulk Pharmaceutical Trade Data, 1997 - 1998 5.6.119: Leading Foreign Pharmaceutical Operations in South Korea, 1998 5.6.120: South Korean Pharmaceutical Classification, 1999 5.6.121: EU Product Market Share in South Korea, 1997 5.6.122: Proton Pump Inhibitor Sales in South Korea, 1998 - 1999 5.6.123: South Korean Reimbursement Prices 5.6.124: South Korean Reimbursement on Imported Drugs, 1998 5.6.125: South Korean Anticancer Market, 1998 5.6.126: South Korean Anti-Ulcer Market Value 5.6.127: South Korean Oral Antifungal Market
Sri Lanka 5.6.128: Sri Lankan Pharmaceutical Market
Taiwan 5.6.129: Pharmaceutical Market in Taiwan, 1998 5.6.130: Implications of Taiwanese Pricing Policies, 1990 - 1999 5.6.131: Government Revenue from Taiwanese Patient Co-Payments, 1999 5.6.132: Prevalence of Hepatitis B in Taiwan
Thailand 5.6.133: The Thai Pharmaceutical Market, 1998 - 1999 5.6.134: Thai Pharmaceutical Market Forecast, 1999 5.6.135: The Thai Prescription Pharmaceutical Market, 1998 5.6.136: Thai Market for Imported Pharmaceutical Products, 1998 - 1999 5.6.137: Potential Thai Pharmaceutical Market for PhRMA Members, 1999 5.6.138: Pharmaceutical Counterfeiting in Thailand 5.6.139: Incidence of Impotence in Thailand 5.6.140: Incidence of Influenza in Thailand 5.6.141: Prevalence of HIV in Thailand
Vietnam 5.6.142: Vietnamese Pharmaceutical Market, 1998 - 2005 5.6.143: Value of Imports to Vietnam, 1998 5.6.144: Vietnamese Domestic Pharmaceutical Sector Exports, 1998 5.6.145: Vietnam's Pharmaceutical Exports to the Eastern Bloc, 1998 5.6.146: Vietnamese Pharmaceutical Joint-Ventures Output, 1998
5.7: NEAR/MIDDLE EAST
India 5.7.1: Indian Pharmaceutical Imports, 1996/97 5.7.2: Indian Pharmaceutical Trade, 1997/98 5.7.3: Indian Pharmaceutical Exports to Algeria, 1998 5.7.4: Sales Forecast for Indian Herbal Products, 1999 - 2004 5.7.5: Forecast for Growth in the Indian Pharmaceutical Industry 5.7.6: Cost to US Companies of India's Patent Regime 5.7.7: Pharmaceutical Prices in India, 1995 - 1998 5.7.8: Average Pharmaceutical Formulation Production Price Levels in India 5.7.9: Forecast for HIV-Infection in India, 2000 5.7.10: Incidence of Leprosy in India
Iran 5.7.11: Leading Therapeutic Categories in Iran, 1998 5.7.12: Leading Pharmaceutical Products in Iran, 1998 5.7.13: Top Ten Pharmaceutical Companies in Iran, 1998 5.7.14: Iranian Pharmaceutical Market, 1998 5.7.15: Iranian Budget for Pharmaceuticals, 2000 5.7.16: Blood Product Requirements in Iran 5.7.17: Iranian Consumption of Boric Acid
Israel 5.7.18: Israeli Biotechnology Industry Data, 1997 - 1999
Jordan 5.7.19: Jordanian Pharmaceutical Production, 1998 5.7.20: Jordanian Pharmaceutical Consumption, 1998 5.7.21: Jordanian Pharmaceutical Trade Data, 1998 5.7.22: Annual US Cost of Jordanian Copies of Patented Pharmaceuticals
Lebanon 5.7.23: Healthcare Expenditure in Lebanon, 1997 5.7.24: Debts to Lebanese Hospitals, 1996 - 1999 5.7.25: Private Medical Insurance in Lebanon
Pakistan 5.7.26: The Pharmaceutical Market in Pakistan 5.7.27: Pharmaceutical Price Cuts in Pakistan, 1999 5.7.28: Impact of Medicines Tax in Pakistan, 1999
United Arab Emirates 5.7.29: Healthcare Improvements in the United Arab Emirates
5.8: RUSSIA AND THE FORMER SOVIET UNION
Russia 5.8.1: Russian Pharmaceutical Market, 1998 - 1999 5.8.2: Number of Russians Eligible for Medicine Reimbursement 5.8.3: Prevalence of Diabetes in Russia 5.8.4: Russian Market for Contraceptives, 1999 5.8.5: Incidence of HIV in the Former Soviet Union, 1999
Ukraine 5.8.6: Ukrainian Pharmaceutical Market Value, 1997 - 1998 5.8.7: Ukrainian Pharmaceutical Market Data 5.8.8: Ukrainian Market Figures, 1997 - 1999 5.8.9: Ukrainian Pharmaceutical Sales by Leading Therapeutic Categories, 1998 5.8.10: Leading Pharmaceutical Companies in Ukraine by Sales, 1998 5.8.11: Health Expenditure in Ukraine, 1997 - 1999
INDEX
© PJB Publications Ltd. 2000 All rights reserved. |